Posted by Michael Wonder on 26 Oct 2018
Institute for Clinical and Economic Review report finds extended-release treatments for opioid use disorder provide only marginal benefits over generic alternatives, at significantly higher prices
25 October 2018 - ICER report includes value-based annual price ranges for Probuphine, Vivitrol, and CAM2038.
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of extended-release medications for the treatment of opioid use disorder. The report focuses on a buprenorphine implant (Probuphine, Titan), an extended-release naltrexone injection (Vivitrol, Alkermes), and two extended-release buprenorphine injections: CAM2038 (Braeburn), an investigational agent currently under FDA review, and Sublocade (Indivior).
This Evidence Report will be the subject of an upcoming public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), in Newton, MA on 8 November 2018. The New England CEPAC is one of ICER’s three independent evidence appraisal committees comprising medical evidence experts, practicing clinicians, methodologists, and leaders in patient engagement and advocacy.
